ICCM Q3'26 Earnings: EPS estimate is (1.16) USD

ICCM (IceCure Medical Ltd.) will release Q3'26 earnings on November 18. Analysts expect revenue of 876.50 thousand USD and an EPS of (1.16) USD. The announcement is scheduled for 7:30 AM ET (12:30 PM UTC).

Original reporting
Published Nov 17, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ICCM Q3'26 Earnings: EPS estimate is (1.16) USD — source image
Decision brief

The 30-second read

$ICCMNeutralMed
01

Why it matters

The main trading relevance is timing and the direction implied by negative consensus EPS, which can influence positioning into the print.

02

Market read

This is a pre-earnings setup for ICCM with consensus EPS of -1.16 and revenue of $876.5k, likely to drive near-term volatility around the release.

03

What to watch

For micro/small-cap biotech, investors often react to cash runway, trial or regulatory updates, and management commentary; none of those details are included here.

Relevance 5/10Novelty 4/10Timing: pre-market Nov. 18, results expected at 7:30 AM ET

Background

The article frames ICCM’s upcoming Q3'26 earnings release date and consensus estimates for revenue and EPS.

Company-level read

Ticker impact

$ICCMNeutralMedium confidence
Context

ICCM is scheduled to report Q3'26 results Nov. 18 pre-market, with consensus EPS expected at -1.16 and revenue at $876.5k.

Expected impact

Potential volatility around whether reported EPS and revenue come in better or worse than the -1.16 EPS and $876.5k revenue expectations.

Evidence & confidence

The article provides the upcoming earnings timing and consensus estimates, which can drive pre-earnings positioning and post-print repricing if results deviate.

Market effects

Limited read-through to the broader biotech/medical-device space because the article is a single-company earnings setup with small absolute revenue.

Minimal, as the catalyst is company-specific and not a macro release.

Low, since the disclosure is not tied to global policy, commodities, or cross-market flows.

Counterpoint

Because the piece is only a scheduled earnings preview with consensus numbers, price action may be driven more by guidance or cash-burn commentary than by the headline EPS/revenue estimates.

Key entities

  • ICCM

    IceCure Medical Ltd., scheduled to report Q3'26 results on Nov. 18 before market open.

Related articles

$ICCMMed

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.

$ICCMMedAI 8/10

A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.